Gain Therapeutics (GANX) Financials

$1.80

$-0.02 (-1.10%)

As on 04-Sep-2026 18:46EDT

Market cap

$79 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

6.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	0.06	0.14	0.16
Cost of Revenue	-4.83	0.09	0.08	0.08	8.24	7.16
Gross Profit	4.83	-0.09	-0.08	0.06	0.14	0.16
Operating Expenses	19.29	18.71	20.35	22.31	17.92	13.99
Operating Profit (EBIT)	-19.29	-18.71	-20.35	-22.25	-17.78	-13.83
Other Income	--	--	--	--	-0.10	--
Profit before Tax	-19.20	-19.30	-19.87	-22.19	-17.50	-13.89
Provision for Tax	0.91	0.86	0.54	0.08	0.09	0.00
Profit after Tax (Net Income)	-20.11	-20.16	-20.41	-22.27	-17.59	-13.89
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-17.59	-13.89

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	11.29	18.56	7.34	12.58	18.88	34.82
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.70	0.90	0.87	1.08	1.09	1.61
Current Liabilities	3.43	3.35	3.91	4.95	4.13	2.55
Total Liabilities	18.86	22.82	12.12	18.61	24.10	38.99

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.45	0.58	0.52	0.83	3.01	1.26
Current Assets	14.97	22.24	11.60	17.78	21.09	37.72
Total Assets	30.39	22.82	12.12	18.61	24.10	38.99
Total Debt*	0.61	0.73	0.65	1.03	1.27	1.61
Net Current Assets	--	18.88	7.69	12.83	16.97	35.17

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-18.47	-18.87	-18.87	-14.69	-12.37
Cash Flow from Investing Activities	--	--	4.98	10.22	-14.77	-0.09
Cash from Financing Activities	--	28.45	13.01	12.64	-0.08	41.77
Net Cash Inflow / Outflow	--	--	--	--	-29.55	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.53	-0.61	-0.75	-1.37	-1.48	-1.37
Cash EPS ($)	--	-0.61	-0.75	-1.37	-1.47	-1.36
Adjusted Book Value ($)	--	0.56	0.27	0.78	1.59	3.43
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.56	-0.70	-1.16	-1.24	-1.22
Free Cash Flow per Share ($)	--	-0.56	-0.70	-1.17	-1.25	-1.23

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-147.76	-189.01	-131.92	-62.18	-63.30
ROE (%)	-134.68	-155.66	-204.95	-141.57	-65.52	-67.73
ROA (%)	-88.53	-115.39	-132.83	-104.28	-55.77	-57.18
EBIT Margin (%)	--	--	--	-40,210.67	-12,488.77	-8,416.43
Net Margin (%)	--	--	--	-40,354.33	-39,948.08	-8,418.86
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	-1.00	-0.61	-0.15	4.71
EBIT Growth (%)	-7.65	2.89	10.43	-26.81	-26.00	-299.10
Net Profit Growth (%)	-8.14	1.23	8.34	-26.59	-26.64	-288.26
EPS Growth (%)	19.30	0.19	0.45	0.07	-0.08	-3.33
Book Value Growth (%)	116.18	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-5.27	-2.87	-2.38	-2.11	-3.97
Price / Book Value	6.84	5.72	7.98	4.21	1.97	1.59
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.55	-4.48	-2.47	-1.68	-1.05	-1.44
Close Price ($)	2.03	3.22	2.16	3.27	3.13	5.43
High Price ($)	4.34	4.34	5.33	6.19	6.70	17.93
Low Price ($)	1.41	1.41	0.89	2.00	2.33	5.25
Market Cap ($ Cr)	78.56	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.04	0.09	0.08	0.07	0.05
Short term debt to equity ratio	0.02	0.01	0.04	0.03	0.02	0.01
Current Ratio	4.36	6.63	2.97	3.59	5.11	14.78
Quick Ratio	4.36	--	--	--	--	--
Interest Coverage	--	--	--	--	-70.73	-117.82

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	439.61	74.14	118.46
Asset Turnover	--	--	--	0.00	0.00	0.01
Receivable days	--	--	--	1,146.63	390.16	225.79
Inventory Days	--	--	--	--	--	69.20
Payable days	--	3,439.61	4,920.68	6,691.08	48.44	38.80
Cash Conversion Cycle	--	--	--	--	--	256.20

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.